[The Lancet Oncology Commission] The human crisis in cancer: a Lancet Oncology Commission Amid unprecedented scientific progress in oncology, a growing body of evidence reveals a parallel and profound crisis in the human experience of cancer care. Despite overall survival outcomes improving, the systems designed to deliver care increasingly fall short in addressing the emotional, relational, and existential dimensions of cancer. Although examples of compassionate and attentive care can be found in every… The Lancet Oncology November 26, 2025 Original source
[Articles] Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study This study met its primary endpoint, showing high clinical activity of pembrolizumab plus lenvatinib, but with substantial toxicity, in patients with pleural mesothelioma who had progressed after first-line nivolumab plus ipilimumab. This drug combination is promising for future studies in pleural mesothelioma. The Lancet Oncology November 26, 2025 Original source
[Articles] Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial Vorasidenib reduced tumour growth rate and improved seizure control compared with placebo, with no observed negative effects on HRQOL or neurocognition. Additional follow-up supported the robustness of progression-free survival and time to next intervention in patients with grade 2 IDH1/2-mutant diffuse glioma. These findings support the use of vorasidenib in patients with grade 2 IDH1/2-mutant gliomas who only had surgical… The Lancet Oncology November 26, 2025 Original source
[Articles] Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial MB-FUS plus temozolomide is a safe combinatorial therapeutic approach for individuals with high-grade glioma, with the potential to improve survival and enable non-invasive plasma biomarker-based disease surveillance (sono-liquid biopsy), warranting randomised controlled trials. The Lancet Oncology November 26, 2025 Original source
[Articles] A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group The proposed RANO classification for extent of resection could serve as a tool for prognostic stratification. Although associations between survival and extensive surgery are evident sooner in patients with astrocytoma, supramaximal resection also translates into survival benefits for patients with oligodendrogliomas. The Lancet Oncology November 26, 2025 Original source
[Articles] Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial Our study met the primary endpoint, showing antitumour activity (clinical complete response rates) and a manageable safety profile for ezabenlimab and mDCF induction when given with INRT in patients with locally advanced SCAC, enabling personalised INRT, and supporting phase 3 trials of this treatment in patients with stage 3 SCAC. The Lancet Oncology November 26, 2025 Original source
[Articles] Total neoadjuvant therapy followed by non-operative management or surgery in stage II–III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial In pMMR/MSS stage II–III rectal cancer, total neoadjuvant therapy followed by non-operative management allows organ preservation in some patients without compromising distant relapse-free survival, supporting non-operative management as a treatment option in clinical practice. The Lancet Oncology November 26, 2025 Original source
[Articles] Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study At final analysis, camrelizumab plus rivoceranib continued to show clinically meaningful survival improvement compared with sorafenib, with manageable safety. The extended follow-up further confirmed the benefit-to-risk profile of camrelizumab plus rivoceranib, supporting the combination as a new first-line treatment option for unresectable hepatocellular carcinoma. The Lancet Oncology November 26, 2025 Original source
[Articles] Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials With adequate follow-up, distant disease-free survival is a robust surrogate endpoint for predicting final overall survival outcomes in neoadjuvant RCTs for early breast cancer in most contexts. However, the distant disease-free survival surrogacy appears to be weak for the hormone receptor-positive and HER2-negative and for the hormone receptor-positive and HER2-positive molecular subtypes. These latter findings warrant further investigation in more… The Lancet Oncology November 26, 2025 Original source
[Articles] Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial In this exploratory, long-term analysis, extended adjuvant metronomic capecitabine provided durable disease-free survival benefit in early triple-negative breast cancer, although the findings should be interpreted with caution given the post-hoc nature of the analysis. Patients with FOXC1-high tumours showed a survival advantage with capecitabine versus observation; if this finding is validated, FOXC1-driven patient selection might be useful to optimise therapeutic… The Lancet Oncology November 26, 2025 Original source
[Articles] Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial Fuzuloparib, either as monotherapy or in combination with apatinib, provided statistically significant improvements in progression-free survival compared with chemotherapy in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations, presenting as new treatment options. The Lancet Oncology November 26, 2025 Original source
[Articles] Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial Pirfenidone in combination with glucocorticoids provides a potential therapeutic strategy for grade 2 or grade 3 radiation-induced lung injury, addressing the unmet clinical need for effective antifibrotic therapy in patients receiving thoracic radiotherapy. Further investigation is needed to validate these findings in patients with worse radiation-induced lung injury than was studied here. The Lancet Oncology November 26, 2025 Original source
[Articles] Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study Participant selection using the PLCOm2012 risk prediction model with a 6-year risk of at least 1·58% cutoff is more efficient and effective in detecting lung cancer than the NELSON criteria and should therefore be implemented in lung cancer screening programmes. The Lancet Oncology November 26, 2025 Original source
[Perspectives] When healing means letting go I once believed that healing meant curing—that a good doctor must fight relentlessly against disease, offering every patient another chance, another line of therapy, another sliver of hope. My instinct was always to do more. But one patient taught me that sometimes, the truest form of healing begins when we learn to let go. The Lancet Oncology November 26, 2025 Original source
[Perspectives] Humour in the face of hardship Cancer—It Could Be Worse? (self-published, 2025) is T Fronks’ first book and an energetic, light-hearted addition to the cancer autobiography genre. Fronks, who lives in North Wales, UK, intersperses humorous and optimistic prose with over 50 witty poems and illustrations that she composed during her experience with breast cancer. The memoir presents a bank of enjoyable analogical descriptions and cultural… The Lancet Oncology November 26, 2025 Original source
[Perspectives] Cancer revolution: science, innovation, and hope A stone's throw from Dublin's Merrion Square, where medical luminaries such as William Stokes and William Wilde plied their craft, stands the airy Georgian structure of the St Stephen's Green Centre. Typically housing an assortment of boutiques and galleries, it is, until Oct 31, 2025, hosting something more unusual, Cancer Revolution: Science, Innovation and Hope, a major new exhibition by… The Lancet Oncology November 26, 2025 Original source
[Perspectives] Cancer and comedy: a review of three stand-up specials A cancer diagnosis does not leave much room for humour, but this year I saw three stand-up comedians who found plenty to talk about and took to the stage to share it with London audiences. The Lancet Oncology November 26, 2025 Original source
[News] Government shutdown and Medicare changes impact cancer care in the USA The effects of Medicare funding cuts and the longest ever shutdown of the US Federal Government have slowed momentum to a standstill in cancer prevention, screening, and treatment, warned the Association of American Cancer Institutes (AACI), which represents more than 100 academic and freestanding cancer centres in the USA and Canada. The Lancet Oncology November 26, 2025 Original source
[News] More e-cigarette users than cigarette smokers for the first time in the UK The number of adults using e-cigarettes or vapes has exceeded the number of cigarette smokers in the UK for the first time, according to figures released on Nov 4, 2025, from the Office for National Statistics. The Lancet Oncology November 26, 2025 Original source
[News] Europe's Beating Cancer Plan delayed by “legislative inaction” The success of Europe's Beating Cancer Plan (EBCP) is at risk of being undermined by slow progress on alcohol, tobacco, and nutrition control, according to an implementation findings study published on Oct 20, 2025. The Lancet Oncology November 26, 2025 Original source